

Joint statement: Access to continuous glucose monitors for adults living with type 2 diabetes in London

The NHS London Procurement Partnership and the London Diabetes Clinical Network are currently developing an approach to guide implementation of the [NICE NG28 guidelines](#) (updated Mar 2022), which extended access to continuous glucose monitoring (CGM) to eligible individuals living with type 2 diabetes likely to benefit from these technologies (link to eligibility criteria [here](#)).

The NICE NG28 Clinical guidelines and the London implementation documents refer to a number of new-to-market CGM devices that are available for prescribing on FP10 prescriptions. These devices were added to the National Drug Tariff in August 2022.

We work with all London ICS's to enable implementation equitably across London. The documents are being commented on widely by key stakeholders across London to ensure that they meet this aim.

The implementation approach will proceed through governance at London and ICS level before it is finalised.

Local policies and procedures within each ICS will need to be followed for the introduction and approval for prescribing these CGM devices.

We encourage prescribers to work closely with their local medicines optimisation teams to ensure that CGM devices are prescribed in line with current local processes.

Sincerely,

NHS London Procurement Partnership

London Diabetes Clinical Network – NHS England, London Region